Empowered Funds LLC Makes New $19.94 Million Investment in United Therapeutics Corporation $UTHR

Posted by George Bondi on Aug 28th, 2026

Empowered Funds LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 36,800 shares of the biotechnology company’s stock, valued at approximately $19,939,000.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in United Therapeutics during the second quarter worth about $2,868,735,000. Avoro Capital Advisors LLC raised its position in shares of United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC grew its holdings in United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after buying an additional 295,221 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after buying an additional 70,829 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Bank of America decreased their target price on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $646.00.

View Our Latest Research Report on United Therapeutics

United Therapeutics Trading Up 2.2%

Shares of United Therapeutics stock opened at $527.91 on Friday. The company’s 50-day moving average price is $530.89 and its two-hundred day moving average price is $538.86. The stock has a market cap of $22.64 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $6.41 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $517.28, for a total value of $4,914,160.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,827,875.04. This trade represents a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 424,075 shares of company stock worth $227,336,485. Company insiders own 8.60% of the company’s stock.

United Therapeutics Profile

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.